Summit Therapeutics plc Summit Therapeutics Plc : Director/Pdmr Shareholding
19 July 2018 - 4:00PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Exercise of Restricted Stock Units and Director Dealings
Oxford, UK, and Cambridge, MA, US, 19 July 2018 - Summit Therapeutics
plc (AIM: SUMM, NASDAQ: SMMT), announces the exercise by the following
Non-Executive Directors of restricted stock units ('RSUs') that entitled
the holder to subscribe for an ordinary share of one penny nominal value
at a subscription price of one penny per ordinary share. The RSUs were
granted under the Company's 2017 Remuneration Policy and were eligible
for exercise for a limited time after completion of a vesting period of
one year. Details of the exercise of the RSUs, all of which took place
on 18 July 2018, and which have been duly notified to the Company, are
summarised below.
Director Position RSU's Exercised
Frank Armstrong Non-Executive Chairman 41,096
Barry Price Non-Executive Director 19,179
Stephen Davies Non-Executive Director 19,179
Leopoldo Zambeletti Non-Executive Director 19,179
Valerie Andrews Non-Executive Director 19,179
Dave Wurzer Non-Executive Director 19,179
Total 136,991
Summit has also been notified that Barry Price and Leopoldo Zambeletti
have sold 9,851 and 11,286 ordinary shares, at a price of 36.5 pence per
ordinary share for the two separate transactions, to cover the tax and
other charges associated with the exercise of the RSUs.
Following the exercise of the RSUs, the shareholdings of the
Non-Executive Directors are as follows:
Shareholding % of Issued Share
Director Position (ordinary shares) Capital
Non-Executive
Frank Armstrong Chairman 80,538* 0.10%
Non-Executive
Barry Price Director 116,539 0.14%
Non-Executive
Stephen Davies Director 621,660 0.76%
Non-Executive
Leopoldo Zambeletti Director 7,893 0.01%
Non-Executive
Valerie Andrews Director 29,679 0.04%
Non-Executive
Dave Wurzer Director 26,679 0.03%
Total 882,988 1.08%
* Includes shares held by persons closely associated with the director
Application has been made to the London Stock Exchange for the admission
of 136,991 ordinary shares to trading on AIM and it is expected that
admission will become effective and that dealings will commence at 8.00
a.m. on 24 July 2018.
Following the exercise of these RSUs, the total number of ordinary
shares following admission will be 82,125,995 with each ordinary share
carrying the right to one vote. The Company has no shares in Treasury;
therefore following admission the total number of voting rights in
Summit will be 82,125,995. This figure may be used by shareholders as
the denominator for the calculations by which they will determine if
they are required to notify an interest in, or change to their interest
in, the share capital of the Company under the FCA's Disclosure and
Transparency Rules.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014 (MAR).
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients, and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
Notification of Transactions pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the persons discharging managerial responsibilities/person
closely associated
a) Name
1. Frank Armstrong
2. Barry Price
3. Stephen Davies
4. Leopoldo Zambeletti
5. Valerie Andrews
6. Dave Wurzer
2 Reason for the notification
a) Position / status
1. Non-Executive Chairman
2. Non-Executive Director
3. Non-Executive Director
4. Non-Executive Director
5. Non-Executive Director
6. Non-Executive Director
b) Initial notification / Initial notification
Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Summit Therapeutics plc
b) LEI 213800NRW8AOMYMTBD89
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a) Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
Identification code GB00BN40HZ01
b) Nature of the Exercise of restricted stock units (RSUs) to subscribe
transactions for ordinary shares of one penny nominal value
c) Price(s) and volume(s) Price(s) Volume(s)
(i)-(vi) 1p (exercise price)
1. 41,096
(ii)-(vi) 19,179
d) Aggregated information
- Aggregated volume 136,991 ordinary shares
- Price 1 penny (exercise price)
e) Date of the 18 July 2018
transactions
f) Place of the Outside a trading venue
transactions
1 Details of the persons discharging managerial responsibilities/person
closely associated
a) Name
1. Barry Price
2. Leopoldo Zambeletti
2 Reason for the notification
a) Position / status
1. Non-Executive Director
2. Non-Executive Director
b) Initial notification / Initial notification
Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Summit Therapeutics plc
b) LEI 213800NRW8AOMYMTBD89
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a) Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
Identification code GB00BN40HZ01
b) Nature of the Sale of ordinary shares of one penny nominal value
transactions
c) Price(s) and volume(s) Price(s) Volume(s)
1. 36.5 pence 1. 9,851
2. 36.5 pence 2. 11,286
d) Aggregated information
- Aggregated volume 21,137 ordinary shares
- Average Price 36.5 pence
e) Date of the 18 July 2018
transactions
f) Place of the London Stock Exchange
transactions
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
July 19, 2018 02:00 ET (06:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024